Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Net Margin of 23.32% for Q1 2026, up 134.0% year-over-year from 9.96% in Q1 2025, and up 168.44% quarter-over-quarter from 8.69% in Q4 2025.
Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Net Margin data on file, last reported at 23.32% in Q1 2026.
- Net Margin for Q1 2026 came in at 23.32%, up 134.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.0% (up 382.0% YoY), and the FY2025 annual result was 14.64%, up 3314.0% from the prior year.
- Net Margin improved to 23.32% in Q1 2026 per CELG-RI's latest filing, from 8.69% in the prior quarter.
- Over five years, Net Margin peaked at 23.32% in Q1 2026 and troughed at 100.36% in Q1 2024.
- A 5-year average of 7.77% and a median of 14.33% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin plunged 12036 bps in 2024, then surged 12234 bps in 2025.
- A 5-year view of Net Margin shows it stood at 17.75% in 2022, then decreased by 16 bps to 14.87% in 2023, then slumped by 96 bps to 0.62% in 2024, then soared by 1311 bps to 8.69% in 2025, then soared by 168 bps to 23.32% in 2026.
- Business Quant data shows CELG-RI's Net Margin at 23.32% in Q1 2026, 8.69% in Q4 2025, and 17.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 23.32% |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 23.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.32% |
| Dec 31, 2025 | 8.69% |
| Sep 30, 2025 | 17.96% |
| Jun 30, 2025 | 10.70% |
| Mar 31, 2025 | 21.98% |
| Dec 31, 2024 | 0.62% |
| Sep 30, 2024 | 9.73% |
| Jun 30, 2024 | 13.36% |
| Mar 31, 2024 | -100.36% |
| Dec 31, 2023 | 14.87% |
| Sep 30, 2023 | 17.64% |
| Jun 30, 2023 | 18.50% |
| Mar 31, 2023 | 20.00% |
| Dec 31, 2022 | 17.75% |
| Sep 30, 2022 | 14.33% |
| Jun 30, 2022 | 12.02% |
| Mar 31, 2022 | 11.01% |
| Dec 31, 2021 | 19.79% |
| Sep 30, 2021 | 12.74% |
| Jun 30, 2021 | 8.50% |